Moderna shares slide after record $604m US listingRNA drug specialist Moderna smashed the record for an initial public offering (IPO) in the US on Friday, Share XModerna shares slide after record $604m US listinghttps://pharmaphorum.com/news/moderna-shares-slide-after-record-604m-us-listing/
Supernus says ADHD drug trounces rivals, but shares slideSupernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, Share XSupernus says ADHD drug trounces rivals, but shares slidehttps://pharmaphorum.com/news/supernus-says-adhd-drug-trounces-rivals-but-shares-slide/
After delayed IPO, Mereo gets US listing via OncoMed mergerUK biotech Mereo BioPharma is merging with Californian biotech OncoMed in an all-stock deal that swells its pipeline Share XAfter delayed IPO, Mereo gets US listing via OncoMed mergerhttps://pharmaphorum.com/news/after-delayed-ipo-mereo-gets-us-listing-via-oncomed-merger/
Novartis takes Xolair follow-up into phase III hives trialNovartis says it intends to move a drug for chronic spontaneous urticaria (CSU), a severe form of hives, Share XNovartis takes Xolair follow-up into phase III hives trialhttps://pharmaphorum.com/news/novartis-takes-xolair-follow-up-into-phase-iii-hives-trial/
Beckley Canopy Therapeutics raises £7.4m for cannabis R&DOxford-based biopharma Beckley Canopy Therapeutics has raised £7.4 million to develop a range of cannabis-based products for the Share XBeckley Canopy Therapeutics raises £7.4m for cannabis R&Dhttps://pharmaphorum.com/news/beckley-canopy-therapeutics-raises-7-4m-for-cannabis-rd/
GSK enters PARP space with TESARO acquisitionGSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its Share XGSK enters PARP space with TESARO acquisitionhttps://pharmaphorum.com/news/gsk-enters-parp-space-with-tesaro-acquisition/
GBT heads to FDA with sickle cell drug voxelotorGlobal Blood Therapeutics (GBT) has persuaded the FDA to accept biomarker data from a phase III trial of Share XGBT heads to FDA with sickle cell drug voxelotorhttps://pharmaphorum.com/news/gbt-heads-to-fda-with-sickle-cell-drug-voxelotor/
P&G completes acquisition of Merck KGaA’s OTC divisionProcter & Gamble (P&G) has completed its acquisition of Merck KGaA’s Consumer Health business, in a move it Share XP&G completes acquisition of Merck KGaA’s OTC divisionhttps://pharmaphorum.com/news/pg-completes-acquisition-merck-kgaas-otc-division/
AbbVie, Pfizer reach licencing agreement for biosimilar HumiraAbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries Share XAbbVie, Pfizer reach licencing agreement for biosimilar Humirahttps://pharmaphorum.com/news/abbvie-pfizer-reach-licencing-agreement-for-biosimilar-humira/
Celgene scores at ASH18 with double luspatercept dataA pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have Share XCelgene scores at ASH18 with double luspatercept datahttps://pharmaphorum.com/news/celgene-scores-at-ash18-with-double-luspatercept-data/
Alkermes preps filing for weight-friendly schizophrenia drugAlkermes is planning to head to the FDA next year with a new schizophrenia drug that, according to Share XAlkermes preps filing for weight-friendly schizophrenia drughttps://pharmaphorum.com/news/alkermes-preps-filing-for-weight-friendly-schizophrenia-drug/
Vectura takes £40 million hit as asthma drug fails trialVectura has abandoned a late-stage drug in severe uncontrolled asthma after it failed a phase 3 trial, resulting Share XVectura takes £40 million hit as asthma drug fails trialhttps://pharmaphorum.com/news/vectura-takes-40-million-hit-as-asthma-drug-fails-trial/
Italy free to reimburse off-label Avastin, rules EU courtNovartis and Roche’s long-running battle to try to prevent off-label prescribing of Roche’s Avastin in place of their Share XItaly free to reimburse off-label Avastin, rules EU courthttps://pharmaphorum.com/news/italy-free-to-reimburse-off-label-avastin-rules-eu-court/
Most pharma firms doing little R&D for poorer patientsA ranking of pharma companies developing new medicines for low- and middle-income countries has revealed that just five Share XMost pharma firms doing little R&D for poorer patientshttps://pharmaphorum.com/news/most-pharma-firms-doing-little-rd-for-poorer-patients/
Roche pulls extended use application for kidney cancer drugRoche has withdrawn an application to the European Medicines Agency (EMA) for an expanded use for its immunotherapy Share XRoche pulls extended use application for kidney cancer drughttps://pharmaphorum.com/news/roche-pulls-extended-use-application-for-kidney-cancer-drug/
Merck and Pfizer chalk up another fail for BavencioMerck KGaA and Pfizer’s late entrant to the checkpoint inhibitor category has failed a phase III trial in Share XMerck and Pfizer chalk up another fail for Bavenciohttps://pharmaphorum.com/news/merck-and-pfizer-chalk-up-another-fail-for-bavencio/
Eyeing Novartis deal, Akcea trumpets lipoprotein drug dataIonis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with Share XEyeing Novartis deal, Akcea trumpets lipoprotein drug datahttps://pharmaphorum.com/news/eyeing-novartis-deal-akcea-trumpets-lipoprotein-drug-data/
Entresto tops mainstay ACE inhibitor in heart failure trialTwo years ago, Novartis launched a big trials programme for its heart failure drug Entresto in the hope Share XEntresto tops mainstay ACE inhibitor in heart failure trialhttps://pharmaphorum.com/news/entresto-tops-mainstay-ace-inhibitor-in-heart-failure-trial/
